Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Numinus Wellness Focused on Boosting Profitability and Expanding Community Support (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ARCA Biopharma Inc ABIO

Healthcare Biotechnology
ARCA biopharma, Inc. is a clinical-stage biopharmaceutical company engaged in developing genetically and other targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. The Company's lead product candidate is Gencaro (bucindolol hydrochloride) for the treatment of atrial fibrillation (AF) in patients with chronic heart failure (HF). Gencaro is... see more

Recent & Breaking News (NDAQ:ABIO)

ARCA Biopharma Announces Issuance of European Patent for Treating Cardiovascular Diseases and Conditions With a New Chemical Entity Utilizing Genetic Targeting

GlobeNewswire November 16, 2017

ARCA biopharma Announces Third Quarter 2017 Financial Results and Provides Business Update

GlobeNewswire November 9, 2017

ARCA biopharma to Present at the Sidoti & Company Fall 2017 Conference

GlobeNewswire September 21, 2017

ARCA biopharma Announces Completion of Enrollment for GENETIC-AF Phase 2B Clinical Trial

GlobeNewswire August 16, 2017

ARCA biopharma Announces GENETIC-AF Data and Safety Monitoring Board Recommendation to Complete Phase 2B GENETIC-AF Clinical Trial Based on Efficacy and Safety Data in Phase 2B Interim Analysis

GlobeNewswire August 9, 2017

ARCA biopharma Announces Second Quarter 2017 Financial Results and Provides Business Update

GlobeNewswire August 3, 2017

ARCA Biopharma Announces Database Lock for GENETIC-AF Phase 2B Interim Efficacy Analysis – DSMB Recommendation Anticipated in August 2017

GlobeNewswire June 20, 2017

ARCA Biopharma Announces First Quarter 2017 Financial Results and Provides Business Update

GlobeNewswire May 15, 2017

22 Stocks Moving In Friday's Pre-Market Session

Benzinga.com  April 28, 2017

ARCA biopharma Announces 200th Patient Randomized into the GENETIC-AF Seamless Design Phase 2B/3 Clinical Trial

Business Wire April 26, 2017

ARCA biopharma Announces Fiscal Year 2016 Financial Results and Provides Business Update

Business Wire March 21, 2017

ARCA biopharma Announces 175th Patient Randomized into the GENETIC-AF Phase 2B/3 Clinical Trial

Business Wire March 6, 2017

Anders Hove, MD Joins ARCA biopharma Board of Directors

Business Wire February 21, 2017

ARCA biopharma Announces 150th Patient Randomized into the GENETIC-AF Phase 2B/3 Clinical Trial

Business Wire January 18, 2017

ARCA biopharma to Present at Biotech Showcase 2017

Business Wire January 4, 2017

StockNewsNow.com Publishes New SNNLive Video Interview with ARCA biopharma, Inc. Provides Company Overview and Discusses Clinical Development

PR Newswire November 15, 2016

ARCA biopharma Announces Third Quarter 2016 Financial Results and Provides Business Update

Business Wire November 14, 2016

ARCA biopharma Announces Randomization of First European Patients in GENETIC-AF Phase 2B/3 Clinical Trial

Business Wire October 6, 2016

ARCA biopharma to Present at the Dawson James Securities Second Annual Growth Stock Conference

Business Wire October 4, 2016

ARCA biopharma Named Winner of Corporate LiveWire Healthcare and Lifesciences Innovation Award

Business Wire September 13, 2016